Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

OSTEOPORE LIMITED Capital/Financing Update 2020

Aug 18, 2020

65512_rns_2020-08-18_b8baa617-1ca1-4639-909c-9f5fc8f8dafe.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

Market Announcement

==> picture [33 x 50] intentionally omitted <==

19 August 2020

==> picture [451 x 5] intentionally omitted <==

Osteopore Limited (ASX: OSX) – Trading Halt

Description

The securities of Osteopore Limited (‘OSX’) will be placed in trading halt at the request of OSX, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Friday, 21 August 2020 or when the announcement is released to the market.

Issued by

Jessica Coupe

Adviser, Listings Compliance (Perth)

Market Announcement 1/1 ASX Customer Service Centre 131 279 | asx.com.au

19 August 2020 ASX Limited

==> picture [130 x 44] intentionally omitted <==

ASX RELEASE│OSTEOPORE LIMITED

ASX Advisor Listing Compliance Level 40, Central Park 152-158 St Georges Terrace Perth WA 6000

TRADING HALT REQUEST

19 August 2020: Osteopore Limited (ASX: OSX) (“Osteopore” or the “Company”) hereby requests that its securities be placed in a trading halt and provides the following information in accordance with ASX Listing Rule 17.1.

  1. The Company requests a trading halt effective immediately, pending the release of an announcement in relation to a capital raise.

  2. The Company requests that the trading halt remain in place until the earlier of the Company releasing an announcement, or the commencement of trading on Friday, 21 August 2020.

  3. The Company expects that the trading halt will end by the Company making an announcement in relation to a capital raise.

  4. The Company is not aware of any reason why the trading halt should not be granted.

This announcement has been approved for release by the Board of Osteopore.

For more information please contact:

Geoff Pocock

Executive Director Osteopore Limited +61 4 1219 4373 [email protected]

Osteopore Limited (ACN 630 538 957)│ASX:OSX│16 Ord Street, West Perth│+618 9482 0500│www.osteopore.com